治疗糖尿病肾病新药的临床研究现状

被引：1

作者：

刘沫言 ^{[1
,2
]}

朱晗玉 ^{[1
]}

蔡广研 ^{[1
]}

陈香美 ^{[1
]}

机构：

[1] 解放军总医院肾脏病科肾脏疾病国家重点实验室

[2] 济南军区总医院肾病科

来源：

中华肾病研究电子杂志 | 2013年 / 2卷 / 01期

关键词：

慢性肾脏病; 糖尿病肾病; 终末期肾病; 随机对照试验;

D O I：

暂无

中图分类号：

R587.2 [糖尿病性昏迷及其他并发症]; R692.9 [其他疾病];

学科分类号：

1002 ; 100201 ; 100210 ;

摘要：

糖尿病肾病(DN)是糖尿病的严重并发症之一,是发达国家终末期肾病的首要原因。近些年,基于几项大型的、等级强度高的随机对照试验对目前DN的治疗提出了新的挑战,涌现出一系列治疗DN的"新药"。基于循证医学的角度,针对DN发病机制的治疗靶点,有必要对近年治疗DN的一些较有争议的新药物进行综述。

引用

页码：42 / 47

页数：6

共 17 条

[1] 法舒地尔治疗2型糖尿病伴白蛋白尿的临床观察 [J].

张慧 ;

朱孝春 ;

王莉 ;

钱春平 ;

吕秋 .

东南国防医药, 2011, 13 (01) :66-67

[2] 肾活检患者中糖尿病肾病流行病学特点的变迁 [J].

金波 ;

刘志红 ;

葛永纯 ;

谢红浪 ;

王少凡 ;

伏幼娟 ;

黎磊石 .

肾脏病与透析肾移植杂志, 2009, 18 (02) :133-139

[3] 中国糖尿病的防治和研究 [J].

王克安 .

中华流行病学杂志, 1999, (05) :6-9

[4]

Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events （BEACON）[J] . De Zeeuw, Dick,Akizawa, Tadao,Agarwal, Rajiv,Audhya, Paul,Bakris, George L,Chin, Melanie,Krauth, Melissa,Lambers Heerspink, Hiddo J,Meyer, Colin J,Mcmurray, John J,Parving, Hans-henrik,Pergola, Pablo E,Remuzzi, Giuseppe,Toto, Robert D,Vaziri, Nosratola D,Wanner, Christoph,Warnock, David G,Wittes, Janet,Chertow, Glenn M.American Jour

[5]

Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal results[J] . Juan F. Navarro-González,Mercedes Muros,Carmen Mora-Fernández,Haridian Herrera,Beatriz Meneses,Javier García.Journal of Diabetes and Its Complications . 2011 (5)

[6]

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial[J] . Edmund J. Lewis,Julia B. Lewis,Tom Greene,Lawrence G. Hunsicker,Tomas Berl,Marc A. Pohl,Dick de Zeeuw,Hiddo Lambers Heerspink,Richard D. Rohde,Robert C. Atkins,Anne T. Reutens,David K. Packham,Itamar Raz.American Journal of Kidney Diseases . 2011 (5)

[7] Rho kinase inhibition in diabetic nephropathy [J].

Komers, Radko .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (01) :77-83

[8]

Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes[J] . Dori Bilik,Laura N. McEwen,Morton B. Brown,Nathan E. Pomeroy,Catherine Kim,Keiko Asao,Jesse C. Crosson,O. Kenrik Duru,Assiamira Ferrara,Victoria C. Hsiao,Andrew J. Karter,Pearl G. Lee,David G. Marrero,Joe V. Selby,Usha Subramanian,William H. Herman.The Journal of Clinical Endocrinology ＆ Metabolism . 2010 (10)

[9]

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes （VITAL study）: a randomised controlled trial[J] . Dick de Zeeuw,Rajiv Agarwal,Michael Amdahl,Paul Audhya,Daniel Coyne,Tushar Garimella,Hans-Henrik Parving,Yili Pritchett,Giuseppe Remuzzi,Eberhard Ritz,Dennis Andress.The Lancet . 2010 (9752)

[10]

Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis[J] . Pantelis A. Sarafidis,Panagiotis C. Stafylas,Panagiotis I. Georgianos,Athanasios N. Saratzis,Anastasios N. Lasaridis.American Journal of Kidney Diseases . 2010 (5)

← 1 2 →